• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
GYN
CMECNE

Polycystic Ovary Syndrome: Making the Diagnosis

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Recall appropriate clinical findings and lab tests to diagnose PCOS
2. Apply the Rotterdam Criteria when making the diagnosis of PCOS

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

An International Guideline for the diagnosis and management of polycystic ovary syndrome (PCOS) was released by the International PCOS Network (2018).  The International Guideline committees included participants from 37 societies and organizations covering 71 countries.  The International Guideline was developed through the Centre for Research Excellence in Polycystic  Ovary Syndrome (CREPCOS), funded by the Australian National Health and Medical Research Council of Australia (NHMRC), in partnership with Monash University, ESHRE and the ASRM. This guideline provides needed definitional criteria to make an accurate diagnosis.

SUMMARY:

PCOS is a complex disorder characterized by varying degrees of ovulatory dysfunction, hyperandrogenism and metabolic disorders. It carries with it risk of cardiovascular disease and diabetes, as well as endometrial cancer.

KEY POINTS:

Diagnostic Criteria

The International Guideline Endorses the Rotterdam Criteria 

  • The Rotterdam Criteria requires two out of three of the following
    • Hyperandrogenism
    • Oligo or amenorrhea
    • Polycystic ovaries on ultrasound
  • Ultrasound not necessary for diagnosis when oligo/anovulation and hyperandrogenism present (however, will complete the phenotype)
  •  Adolescents
    • Both hyperandrogenism and oligo/anovulation must be present
    • Ultrasound not recommended

Diagnosing Hyperandrogenism

Clinical Diagnosis

  • History and physical exam findings of
    • Acne
    • Alopecia
    • Hirsutism
  • In adolescents, clinical findings must be severe
  • Reported unwanted excess hair growth and/or alopecia should be considered significant regardless of observed severity

Laboratory Diagnosis

  • Use one of the following
    • Free testosterone
    • Free androgen index
    • Calculated bioavailable testosterone
  • Consider androstenedione and dehydroepiandrosterone sulfate (DHEAS) if total or free testosterone are not elevated
    • Note that additional information provided will be limited
  • Lab tests for hyperandrogenism unreliable for women using hormonal contraception
    • If lab testing important/required, withdraw hormonal contraception for at least 3 months and use alternate contraceptive during that time
  • Lab testing for hyperandrogenism most useful when clinical findings unclear or absent
  • Routine screening for Cushing Syndrome in patients with hyperandrogenic chronic anovulation not indicated – should only occur if patients have coexisting signs
    • Buffalo hump | Abdominal Striae | Centripetal fat distribution | Hypertension
  • If androgen results are very high compared to lab reference ranges, consider neoplasia
  • The International Guideline recommends against  using AMH as a diagnostic marker for PCOS

Diagnosing Anovulation

  • When Irregular menstrual cycles are present, consider PCOS
  • Irregular Menses should be defined as follows
    • Normal if occurring in year 1 post menarche (considered part of pubertal transition)
    • 1 to <3 years post menarche: <21 or >45 days
    • 3 years post menarche to perimenopasuse: <21 days or  >35 days or <8 cycles per year
    • 1 year post menarche: >90 days for any one cycle
    • Primary amenorrhea: By age 15 or >3 years post thelarche (breast development)

Note: Ovulatory dysfunction can still occur with regular cycles. Confirm anovulation with serum progesterone levels

Ultrasound and Polycystic Ovarian Morphology

  • Do not use for <8 years post menarche
    • High incidence of multifollicular ovaries
  • Transvaginal approach preferred
    • 8 MHz transducer
  • Threshold (either ovary)
    • ≥20 follicles/ovary and/or
    • Ovarian volume ≥10 ml in either ovary

PCOS ICD10 Billing Code: E28.2

Other Diagnostic Considerations

Consider increased risk for metabolic syndrome and other causes of clinical findings  

  • Physical exam
    • Blood pressure | BMI | Waist circumference
  • Look for additional signs of hyperandrogenism and insulin resistance
    • Acne | Hirsutism | Male pattern hair growth | Acanthosis nigricans | Clitoromegaly
  • Laboratory (may be considered in addition to androgen levels depending on clinical scenario)
    • TSH | Prolactin | 17-OH progesterone
    • Consider screening for Cushing syndrome / acromegaly
    • 2-hour oral glucose tolerance test (fasting glucose, 75 g oral glucose load, 2 hour glucose level)
    • Fasting lipid and lipoprotein levels

Metabolic Syndrome Implications

  • Obese women with PCOS who reduce their weight by as little as 5% will have improved pregnancy rates, glucose and lipid levels and reduced hirsutism
  • Women with PCOS have a 2- to 5-fold increased risk of diabetes
    • Fasting glucose levels are poorly predictive of risk
    • The 2 hr glucose tolerance test above should be utilized instead
  • Screen women with PCOS for cardiovascular risk with BMI, fasting lipid and lipoprotein levels, metabolic syndrome risk factors
    • Rescreen periodically as impaired glucose tolerance can develop over time
    • Strongly recommend weight loss, if appropriate, and regular exercise

Note: Nonclassic congenital adrenal hyperplasia (CAH) can mimic PCOS

  • Endocrine testing for nonclassic CAH
    • Screen for CAH with a fasting level of 17-OH progesterone in the morning in the follicular phase
    • If 17-OH progesterone is elevated (normal < 2 ng/mL) follow with an adrenocorticotropic hormone (ACTH) stimulation test
  • Genetic testing for nonclassic CAH
    • CAH is caused by mutations in both copies of the  CYP21A2 gene that codes for the 21-hydroxylase enzyme
    • Hundreds of mutations have been reported, with 12 pathogenic variants account for >90% of cases
    • 3 mutations  (p.V281L, p.P453S, p.P30L) are associated with the milder, nonclassic form
    • Nonclassic CAH is less severe because 20-50% of enzyme activity is still present and symptoms in women are similar to PCOS

Learn More – Primary Sources:

Monash University PCOS Program

ACOG Practice Bulletin No 194: Polycystic ovary syndrome

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

EJE: MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME–PART 1

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME – PART 2

Take a post-test and get CME credits

TAKE THE POST TEST

Want to hear about the latest clinical summaries via ObG Insider?

Get Your Free e-Newsletter »

image_pdfFavoriteLoadingFavorite

< Previous
All GYN Posts
Next >

Related ObG Topics:

PCOS: Targeting Treatments to Improve Reproductive Outcomes and Reduce CVD
Just how Common is Nonclassic Congenital Adrenal Hyperplasia?
Is the DASH Diet Effective for Obese Women with PCOS?
Secondary Amenorrhea: Workup and Diagnosis  

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site